- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01286831
A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444.
June 16, 2017 updated by: GlaxoSmithKline
An Open-label, Single-arm Study to Determine the Excretionbalance and Metabolic Disposition of [14C]GW642444administered as a Single Dose of an Oral Solution to Healthy Malevolunteers
The purpose of this study is to characterise the metabolic disposition of radiolabelled GW642444 when administered orally.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This will be a single-centre, open-label, single-dose study to characterise the metabolic disposition of oral [14C]GW642444.
Six healthy male subjects will be enrolled to ensure at least four fully evaluable subjects.
Each subject will receive a single 200μg oral dose of GW642444 containing 2 μCi (0.074MBq) of [14C]GW642444.
Whilst subjects are inhouse, blood, urine and faecal samples will be collected for a minimum of 168 hours after dosing (7 days) or for up to 240 hours (10 days) depending on amounts of radioactivity still being excreted after Day 5. Faecal sample collection may continue at home for up to 14 days.
Bile samples will be collected using Entero-Test string sampling of duodenal bile.
Plasma will be prepared from blood at various sample times after dosing to measure parent drug and total radiolabelled drug-related material.
Urine and faeces aliquots will be taken to measure total radiolabelled drug-related material.
Samples of urine, faeces, plasma and bile will be transferred into a separate study to characterise and, where feasible, quantify metabolites in these matrices.
Safety and tolerability will be assessed by blood pressure, heart rate, 12- lead electrocardiogram (ECG), clinical laboratory safety tests, and collection of adverse events (AEs).
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Zuidlaren, Netherlands, 9471 GP
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy male aged between 30 and 55 years inclusive, at the time of signing the informed consent. Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population, which are deemed to be clinically relevant, should always be excluded from enrollment.
- Body Mass Index (BMI) within the range 18.5-29.0 kg/m2 (inclusive).
- Subjects who are current non-smokers, who have not used any tobacco products in the 12 month period preceding the screening visit, and have a pack history of ≤ 5 pack years. [number of pack years = (number of cigarettes per day/20) x number of years smoked]
- AST, ALT, alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
No significant abnormality on 12-lead ECG at screening. Selected specific ECG findings that are considered to be significant and will exclude the subject from study participation include, but are not limited to, the following:
- Sinus bradycardia <45bpm
- Sinus tachycardia ≥110bpm
- Multifocal atrial tachycardia (wandering atrial pacemaker with rate >100bpm)
- PR interval >240msec
- Evidence of Mobitz II second degree or third degree atrioventricular (AV) block.
- Pathological Q waves (defined as wide [>0.04 seconds] and deep [>0.4mV (4mm with 10mm/mV setting)] or >25% of the height of the corresponding R wave, providing the R wave was >0.5mV [5mm with 10mm/mV setting], appearing in at least two contiguous leads.
- Evidence of ventricular ectopic couplets, bigeminy, trigeminy or multifocal premature ventricular complexes.
- QTcF ≥450msec or uncorrected QT >600msec or an ECG that is unsuitable for QT measurements (e.g., poor defined termination of the T wave) Note: QTcF ≥450msec or uncorrected QT >600msec should be confirmed by three readings at least 5 minutes apart.
- ST-T wave abnormalities (excluding non-specific ST-T wave abnormalities)
- Right or left complete bundle branch block
- Clinically significant conduction abnormalities (e.g., left bundle branch block, Wolff-Parkinson-White syndrome)
- Clinically significant arrhythmias (e.g., atrial fibrillation with rapid ventricular response, ventricular tachycardia)
- No significant abnormality on the Holter ECG at screening.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
Exclusion Criteria:
A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- As a result of medical interview, physical examination or screening investigations, the principal investigator or delegate physician deems the subject unsuitable for the study. Subjects must not have a systolic blood pressure above 145 mmHg or a diastolic pressure above 90 mmHg.
- Females.
- The subject has been treated for or diagnosed with depression within six months of screening or has a history of significant psychiatric illness.
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- Surgical procedures on digestive tract including corrective surgery for appendicitis (in the 3 months prior to screening) or diverticulitis, cholecystectomy (gallbladder removal), and/or cholelithotomy (gallstone removal).
- History of or current spastic/ hyperactive colon.
- Subjects who do not have regular defecation patterns (regular defined as passing faeces at least once every two days).
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- Any adverse reaction including immediate or delayed hypersensitivity to any β2-agonist or sympathomimetic drug, or known or suspected sensitivity to the constituents of the GW642444formulation for oral administration.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of alcohol/drug abuse or dependence within 12 months of the study. Abuse of alcohol defined as an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males). One unit is equivalent to a 285mL glass of full strength beer or 425mL schooner of light beer or 1 (30mL) measure of spirits or 1 glass (100mL) of wine (NHMRC Guidelines [NHMRC, 2001]).
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 60 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Participation in a clinical trial involving administration of 14C-labelled compound(s) within the last 12 months. A subjects previous effective dose will be reviewed by the medical investigator to ensure there is no risk of contamination / carryover into the current study.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- The subject has tested positive for HIV antibodies.
- A positive urine drug screen at screening, on admission to the unit, or when randomly tested during the study.
- Positive alcohol urine test at screening or on admission to the Unit.
- Positive urine cotinine test at screening.
- Consumption of seville oranges, pomelos (members of the grapefruit family) or grapefruit juice from 7 days prior to the first dose of study medication.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Subject is mentally or legally incapacitated.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: [14C]GW642444
Single 200μg dose of [14C]GW642444 given on Day 1.
|
Single 200μg dose of [14C]GW642444 given on Day 1.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUC(0-∞), AUC(0-t), Cmax, tmax, λz and t1/2 of total drug-related material (radioactivity) in plasma following oral dosing.
Time Frame: Two months from first dose.
|
Two months from first dose.
|
AUC(0-t), Cmax and tmax of GW642444 following oral dosing.
Time Frame: Two months from first dose.
|
Two months from first dose.
|
Urinary and faecal cumulative excretion as a percentage of the total radioactive dose administered over time.
Time Frame: Two months from first dose.
|
Two months from first dose.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Characterisation of metabolites in plasma, urine, duodenal bile and faecal homogenates.
Time Frame: One year from last subject last visit
|
One year from last subject last visit
|
Vital signs, 12-lead ECG, Clinical laboratory tests, AEs.
Time Frame: Two weeks from first dose.
|
Two weeks from first dose.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 18, 2010
Primary Completion (ACTUAL)
July 9, 2010
Study Completion (ACTUAL)
July 9, 2010
Study Registration Dates
First Submitted
May 6, 2010
First Submitted That Met QC Criteria
January 27, 2011
First Posted (ESTIMATE)
January 31, 2011
Study Record Updates
Last Update Posted (ACTUAL)
June 20, 2017
Last Update Submitted That Met QC Criteria
June 16, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 106181
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study Data/Documents
-
Study Protocol
Information identifier: 106181Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: 106181Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 106181Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 106181Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 106181Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 106181Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: 106181Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on [14C]GW642444
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States, Argentina, Estonia, Canada, Chile, Germany, Peru, Philippines, Mexico, Korea, Republic of, Denmark, Russian Federation, Poland, Slovakia
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveSweden, Norway
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveJapan
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveJapan
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveSouth Africa, United States, Canada, Ukraine, United Kingdom, Denmark, Czechia
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveAustralia, New Zealand
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveAustralia, New Zealand
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom